ABSTRACT
Objective To investigate the effect of budesonide nasal spray and ebastine combined with Xinqin granule on symptom improvement and serum T cell subsets and vascular cell adhesion molecule －1 ( VCAM －1) levels in patients with allergic rhinitis.Methods From February 2015 to April 2017,107 cases of allergic rhinitis in Yuncheng Central Hospital were divided into two groups according to the different ways of treatment .Fifty －three cases in the control group were treated with budesonide nasal spray and ebastine ,54 cases in the study group were treated with Xinqin granule based on the control group.The improvement of nasal congestion ,sneezing,runny nose, nasal itching symptom score and serum VCAM －1,T cell subsets (CD+3 ,CD+4 ,CD+19 ) levels of the two groups were analyzed and compared before treatment and after half a month of the treatment .The clinical effect and incidence of adverse reactions were compared between the two groups.Results After treatment for half a month , the nasal congestion,sneezing,runny nose,nasal itching symptom scores of the study group were lower than those of the control group(all P＜0.05).The clinical effect of the study group [87.04%(47／54)] was higher than that of the control group[67.92%(31／53),χ2 ＝2.970,P＜0.05].After treatment for half a month,the serum VCAM－1,CD+3 ,CD+4 and CD+19 levels in the study group were better than those in the control group [(572.26 ±120.67)ng／L vs.(864.87 ± 238.56)ng／L,(68.69 ±3.31)% vs.(72.08 ±4.29)%,(39.79 ±3.28)% vs.(44.61 ±4.78)%,(10.79 ± 1.64)%vs.(13.61 ±2.18)%] ( all P＜0.05).The incidence rate of adverse reactions in the study group was 11.11%(6／54).which in the control group was 5.66%(3／53),the difference was not statistically significant (χ2 ＝0.445,P＝0.504).Conclusion Budesonide nasal spray and ebastine combined with Xinqin granule in the treatment of patients with allergic rhinitis has significant effect.It can significantly improve the levels of serum VCAM －1 and T cell subsets with high security.
ABSTRACT
Objective@#To investigate the effect of budesonide nasal spray and ebastine combined with Xinqin granule on symptom improvement and serum T cell subsets and vascular cell adhesion molecule-1(VCAM-1) levels in patients with allergic rhinitis.@*Methods@#From February 2015 to April 2017, 107 cases of allergic rhinitis in Yuncheng Central Hospital were divided into two groups according to the different ways of treatment.Fifty-three cases in the control group were treated with budesonide nasal spray and ebastine, 54 cases in the study group were treated with Xinqin granule based on the control group.The improvement of nasal congestion, sneezing, runny nose, nasal itching symptom score and serum VCAM-1, T cell subsets (CD3＋, CD4＋, CD19＋) levels of the two groups were analyzed and compared before treatment and after half a month of the treatment.The clinical effect and incidence of adverse reactions were compared between the two groups.@*Results@#After treatment for half a month, the nasal congestion, sneezing, runny nose, nasal itching symptom scores of the study group were lower than those of the control group(all P<0.05). The clinical effect of the study group[87.04%(47/54)] was higher than that of the control group[67.92%(31/53), χ2=2.970, P<0.05]. After treatment for half a month, the serum VCAM-1, CD3＋, CD4＋ and CD19＋ levels in the study group were better than those in the control group[(572.26±120.67)ng/L vs.(864.87±238.56)ng/L, (68.69±3.31)% vs.(72.08±4.29)%, (39.79±3.28)% vs.(44.61±4.78)%, (10.79±1.64)% vs.(13.61±2.18)%](all P<0.05). The incidence rate of adverse reactions in the study group was 11.11%(6/54). which in the control group was 5.66%(3/53), the difference was not statistically significant (χ2=0.445, P=0.504).@*Conclusion@#Budesonide nasal spray and ebastine combined with Xinqin granule in the treatment of patients with allergic rhinitis has significant effect.It can significantly improve the levels of serum VCAM-1 and T cell subsets with high security.
ABSTRACT
Background: Allergic rhinitis is a ubiquitous aliment affecting a large population of individuals. The mainstay of treatment includes antihistamines and topical steroids. With a large assortment available, the choice of the drugs needs to be non-random and evidenced based. Hence this study was undertaken to compare Levocetrezine and Ebastine in terms of efficacy, safety and cost effectiveness in treatment of allergic rhinitis.Methods: Newly diagnosed patients with allergic rhinitis were categorized into two groups and treated with Levocetrizine 5mg and Ebastine 20mg per day respectively. Severity of the symptoms at the commencement and at the end of second and the fourth weeks of therapy were assessed using a four-point Likert scale and assigning a Total Nasal Symptoms Score (TNSS). The primary efficacy measure was mean change from baseline TNSS at each follow up visit. Change in TNSS was compared using Independent sample test. Adverse effects in both the groups were compared using Chi square test. Cost effectiveness was inferred by calculation of the Average Cost Effectiveness Ratio.Results: A total of 159 patients 84 from Levocetrizine group (L group) and 75 from the Ebastine group (E group) were available for study. At the end of second week, the E group showed a better reduction in TNSS(p-0.04). However, both the groups showed similar reduction in TNSS at the concluding visit (p-value of 0.09). The incidence of adverse effects was significantly higher in the L than in E. Levocetrezine was found to be more cost effective than Ebastine.Conclusions: Levocterezine and Ebastine are equally efficacious in treatment of allergic rhinitis. Hence treatment will have to be personalized to the individual patients based on other factors such as adverse drug effects and cost effectiveness.
ABSTRACT
Objective To observe the clinical efficacy of ebastine combined with Runzao Zhiyang capsules in the treatment of patients with chronic urticaria. Methods A total of 126 patients with chronic urticaria admitted to Department of Dermatology of Tianjin Third Central Hospital from January 2015 to May 2017 were enrolled and they were divided into two groups by the random number table method. The patients in control group (62 cases) were given oral ebastine administration 10 mg once per day, and those in observation group (64 cases) received oral administration of ebastine 10 mg once per day combined with Runzao Zhiyang capsule 2 g, 3 times per day, the therapeutic course being 4 weeks. The changes of clinical efficacy and the symptom scores, including urticaria activity score (UAS) and dermatolo-gical disease life quality index (DLQI) scores of the two groups were observed after treatment of 4 weeks;the incidence of adverse reactions and the recurrence situation after drug withdrawal for 4 weeks at follow-up were analyzed. Results Compared with the control group, the total effective rate of the observation group was significantly increased [92.2% (59/64) vs. 79.0% (49/62), P ＜ 0.05]. After treatment, the overall UAS score and DLQI score in two groups were both significantly decreased, the degree of decrease in observation group were more siginificant than those in control group [UAS: 1.26 (0.52 - 7.35) vs. 1.68 (0.75 - 8.65), DLQI: 0.56±0.52 vs. 1.57±0.96, P ＜ 0.01]. In addition, the total decrease degree of symptom score reducing index (SSRI) in the observation group was significantly greater than that in the control group [(76±21)% vs. (69±23)%, P ＜ 0.05], the incidence of adverse reactions [7.8% (5/64) vs. 12.8% (8/62)] and recurrence rate [8.3% (3/64) vs. 23.8% (5/62)] in the observation group were obviously lower than those in the control group (both P ＜ 0.05). Conclusion The efficacy of ebastine combined with Runzao Zhiyang capsule in the treatment of patients with chronic urticaria is prominent and superior to that of using ebastine alone, the combined method is capable of elevating the therapeutic effect obviously and has less adverse reactions.
ABSTRACT
Objective To prepare ebastine dispersible tablets by hot-melt dispersion method using hypromellose as a carrier.Methods Ebastine was heated to melt and dispersed in hot solution of hypromellose.The mixture was adsorbed by mannitol and then used to prepare dispersible tablets.The characteristics of hot-melt dispersion were analyzed by the methods of differential scanning calorimetry and X-ray powder diffraction.A comparison of dissolution curves between self-made dispersible tablets and original ebastine tablets was performed.Results The analysis of X-ray diffraction and differential scanning calorimetry showed that the ebastine in solid matrix remained the main crystalline characteristics.The dissolution of ebastine hot-melt dispersion was 95.07％ in 15 min in vitro, which was significantly higher than that of micronized ebastine raw material.Moreover, the accumulative dissolution of ebastine dispersible tablets in 30 min was about 30％ higher than the original drug.Conclusion The method of hot-melt dispersion using hypromellose as a carrier improved the ebastine dissolution significantly.
ABSTRACT
Irritable bowel syndrome is a group of functional gastrointestinal disorders with not yet fully clarified etiology. Recent evidence suggesting that mast cells may play a central role in the pathogenesis of irritable bowel syndrome paves the way for agents targeting histamine receptors as a potential therapeutic option in clinical treatment. In this review, the role of histamine and histamine receptors is debated. Moreover, the clinical evidence of anti-histamine therapeutics in irritable bowel syndrome is discussed.
Subject(s)
Gastrointestinal Diseases , Histamine , Irritable Bowel Syndrome , Mast Cells , Receptors, HistamineABSTRACT
OBJECTIVE:To observe clinical efficacy and safety of Ebastine tablet combined with Chushi zhiyang ointment in the treatment of hand keratinizing chapped eczema. METHODS:135 cases of hand keratinizing chapped eczema were divided into control group A(45 cases),control group B(43 cases)and treatment group(47 cases)according to treatment regimen. Control group A was orally given Ebastine tablet,10 mg each time,qd;control group B was given Chushi zhiyang ointment alone,twice a day,morning and evening,applying thin layer of ointment on the affected area;treatment group was given same dose of Ebastine tablet orally and applied Chushi zhiyang ointment on the affected area. 3 groups received treatment for consecutive 4 weeks. Clinical efficacies of 3 groups were observed as well as the scores of pruritus,skin lesion area,keratinization,rhagades and VAS before and after treatment. The occurrence of ADR was compared among 3 groups. RESULTS:The total effective rate of treatment group was 68.09%,which was significantly higher than that of group A(42.22%)and control group B(16.28%),with statistical significance(P0.05). After treatment,above scores of 3 groups decreased significantly,and those of treatment group were significant-ly lower than those of control group A and B,with statistical significance(P0.05). CONCLUSIONS:Ebastine tablet combined with Chushi zhiyang ointment is effective for hand keratinizing chapped eczema,and can significantly improve the skin of patients with good safety.
ABSTRACT
OBJECTIVE: To identify the structure of the primary unknown impurity of ebastine, thus offer technological support for reducing the impurity content and improving the quality of product. METHODS: The primary unknown impurity was separated and extracted from ebastine by preparative HPLC. The structure of the primary unknown impurity was analyzed by EI-MS, NMR, IR and UV and further confirmed with commercial reagent. RESULTS: The primary unknown impurity was elucidated as benzene, 1,1,2,2-tetra-phenyle thane, which is the by-product of ebasline synthesis. CONCLUSION: This study provides reference for the improvement of quality control and process optimization of ebastine.
ABSTRACT
Objective To explore the clinical efficacy of Ebastine joint Compound Glycyrrhizin in treatment of acute and chronic urticarial, and its effect on serum IgE levels.Methods Eighty cases of a-cute and chronic urticaria patients were collected from January 2010 to June 2014 in our hospital for treat-ment.They were randomly divided into control group and observation group, 40 cases in each group, the patients in the control group oral ebastine 10mg 1 times /day, patients in the observation group were given Compound Glycyrrhizin on 75mg and oral ebastine 10mg, 1 times /d, acute urticaria patients were treated for one week of continuous treatment, patients with chronic urticaria were treated for 4 weeks in a row;IgE level was measured by ELISA.Results After treatment, effective rate of patients with acute urticaria was 94.44%in the observation group, the control group was 68.42%; patients with chronic urticaria observa-tion group was 95.45%, the control group was 71.43%, a significant difference ( P <0.05 ) between the observation group and control group.IgE levels in both groups after treatment were reduced compared with before treatment ( P <0.01), after treatment IgE levels of patients had higher degree of improvement in the observation group, differences were statistically significant ( P <0.05).Conclusions The clinical effica-cy of ebastine joint Compound Glycyrrhizin on treatment of acute and chronic urticaria are better than single ebastine, two drugs used in conjunction with synergistic effect by regulating the body's immune function, re-duce allergy strength, improve efficacy.